drugset
drugset / Trial / NCT05052567

CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma

NCT05052567 ↗

Phase 1/2 Completed 50 enrolled Qilu Pharmaceutical Co., Ltd. Cend Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the preliminary safety, efficacy and PK characteristics of cend-1 in patients with advanced metastatic pancreatic ductal adenocarcinoma (Chinese population).

Timeline

Start
2021-10-21
Primary completion
2024-06-29
Completion
2024-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject certepetide Peptide — —

Indications

malignant pancreatic neoplasm